Skip to main content
SpringerLink
Log in

Lymphome diffus à grandes cellules B

  • Chapter
Actualités thérapeutiques dans les lymphomes

  • 562 Accesses

Résumé

Les lymphomes diffus à grandes cellules B (LDGCB ou DLBCL) sont la forme la plus fréquente des lymphomes malins non hodgkiniens. Ils représentent environ un tiers de l’ensemble des lymphomes. Cette entité regroupe des formes agressives, caractérisées à la fois par une évolution spontanée rapide et sévère, et une possibilité de guérison après traitement. Ce sont des entités anatomopathologiques variées. Outre cette variété histologique, l’étude en biologie moléculaire des gènes exprimés dans les LDGCB a permis d’extraire et d’isoler des profils d’expression génique spécifiques à des sous-groupes de LDGCB. Les stratégies thérapeutiques développées jusqu’à présent sont conçues pour être applicables à une entité homogène, même si depuis peu émergent des essais thérapeutiques spécifiques testés en situation de rechute [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Friedberg J (2011) Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011: 498–505

    Google Scholar 

  2. 2. Swerdlow S, Campo E, Harris N, et al. (2008) WHO classification of Tumors of Haematopoietic and Lymphoid tissues. Lyon, France, IARC Press

    Google Scholar 

  3. Ott G, Ziepert M, Klapper W, et al. (2010) Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 116: 4916–25

    Article  PubMed  CAS  Google Scholar 

  4. Tzankov A, Zlobec I, Went P, et al. (2010) Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma 51: 199–212

    Article  PubMed  CAS  Google Scholar 

  5. Mounier N, Briere J, Gisselbrecht C, et al. (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101: 4279–84

    Article  PubMed  CAS  Google Scholar 

  6. Abramson JS, Shipp MA (2005) Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 106: 1164–74

    Article  PubMed  CAS  Google Scholar 

  7. Cuccuini W, Briere J, Mounier N, et al. (2012) MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 119: 4619–24

    Article  PubMed  CAS  Google Scholar 

  8. Savage K, Johnson N, en-Neriah S, et al. (2009) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114: 3533–7

    Article  PubMed  CAS  Google Scholar 

  9. Lenz G, Staudt L (2010) Mechanisms of Disease: Aggressive Lymphomas. N Engl J Med 362: 1417–29

    Article  PubMed  CAS  Google Scholar 

  10. Alizadeh AA (2000) Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 403: 503–11

    Article  PubMed  CAS  Google Scholar 

  11. Rosenwald A, Wright G, Chan WC, et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937–47

    Article  PubMed  Google Scholar 

  12. Monti S, Savage KJ, Kutok JL, et al. (2005) Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105: 1851–61

    Article  PubMed  CAS  Google Scholar 

  13. Dunleavy K, Pittaluga S, Czuczman MS, et al. (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113: 6069–76

    Article  PubMed  CAS  Google Scholar 

  14. Lenz G, Wright G, Dave SS, et al. (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359: 2313–23

    Article  PubMed  CAS  Google Scholar 

  15. Thieblemont C, Briere J, Mounier N, et al. (2011) The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 29: 4079–87

    Article  PubMed  Google Scholar 

  16. Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, et al. (2011) Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 117: 4836–43

    Article  PubMed  CAS  Google Scholar 

  17. Hans CP, Weisenburger DD, Greiner TC, et al. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275–82

    Article  PubMed  CAS  Google Scholar 

  18. (1993) The international Non-Hodkin’s Lymphoma Prognostic Factors project. N Engl J Med 329: 987–94

    Google Scholar 

  19. Haioun C, Itti E, Rahmouni A, et al. (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106: 1376–81

    Article  PubMed  CAS  Google Scholar 

  20. Jerusalem G, Beguin Y, Fassotte MF, et al. (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma. Haematologica 85: 613–8

    PubMed  CAS  Google Scholar 

  21. Fisher RI, Gaynor ER, Dahlberg S, et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328: 1002–6

    Article  PubMed  CAS  Google Scholar 

  22. Coiffier B, Lepage E, Briere J, et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235–42

    Article  PubMed  CAS  Google Scholar 

  23. Vose JM, Link BK, Grossbard ML, et al. (2001) Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 19: 389–97

    PubMed  CAS  Google Scholar 

  24. Miller TP, Dahlberg S, Cassady JR, et al. (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin’s lymphoma. N Engl J Med 339: 21–6

    Article  PubMed  CAS  Google Scholar 

  25. Reyes F, Lepage E, Ganem G, et al. (2005) ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352: 1197–205

    Article  PubMed  CAS  Google Scholar 

  26. Pfreundschuh M, Trumper L, Osterborg A, et al. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7: 379–91

    Article  PubMed  CAS  Google Scholar 

  27. Recher C, Coiffier B, Haioun C, et al. (2011) Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 378: 1858–67

    Article  PubMed  CAS  Google Scholar 

  28. Greb A, Bohlius J, Schiefer D, et al. (2008) High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst Rev: CD004024

    Google Scholar 

  29. Thieblemont C, Grossoeuvre A, Houot R, et al. (2008) Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 19: 774–9

    CAS  Google Scholar 

  30. Peyrade F, Jardin F, Thieblemont C, et al. (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12(5): 460–8

    Article  PubMed  CAS  Google Scholar 

  31. Gisselbrecht C, Glass B, Mounier N, et al. (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28: 4184–90

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’hémato-oncologie, hôpital Saint-Louis, 1, avenue Claude Vellefaux, 75010, Paris, France

    C. Thieblemont

  2. AP-HP, hôpital Saint-Louis, service d’hémato-oncologie, Université Paris VII-Diderot, INSERM U728, France

    C. Thieblemont & M. D. Venon

  3. AP-HP, hôpital Saint-Louis, service d’anatomie pathologique, Université Paris VII-Diderot, INSERM U728, France

    C. Benet & J. Brière

  4. service d’hématologie, CHU de Larchet, Nice, France

    N. Mounier

Authors
  1. C. Thieblemont
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. D. Venon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Benet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Brière
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Mounier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Thieblemont .

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Paris

About this chapter

Cite this chapter

Thieblemont, C., Venon, M.D., Benet, C., Brière, J., Mounier, N. (2013). Lymphome diffus à grandes cellules B. In: Actualités thérapeutiques dans les lymphomes. Springer, Paris. https://doi.org/10.1007/978-2-8178-0371-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0371-5_5

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0370-8

  • Online ISBN: 978-2-8178-0371-5

Publish with us

Policies and ethics

Search

Navigation